Galderma has been granted a patent for a topical liposomal composition designed for enhanced skin delivery. The formulation includes non-palmitoylated hexapeptide-11, tripeptide-1, hexapeptide-12, and tetrapeptide-2, targeting dermal white adipose tissue to promote fat reduction and anti-aging effects. GlobalData’s report on Galderma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Galderma SA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Galderma, Nanoemulsion cosmetics was a key innovation area identified from patents. Galderma's grant share as of July 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Liposomal compositions for skin delivery and fat reduction

Source: United States Patent and Trademark Office (USPTO). Credit: Galderma SA

The granted patent US12053547B2 describes a topical composition that includes a non-palmitoylated hexapeptide-11 encapsulated in liposomes with an average particle size not exceeding 220 nanometers. The hexapeptide-11 is present at a concentration ranging from 0.001 wt. % to 0.05 wt. % of the total composition. Additionally, the formulation incorporates a tripeptide-1, a hexapeptide-12, and a tetrapeptide-2. The claims specify that the hexapeptide-11 may be either non-functionalized or functionalized with a group containing no more than fourteen carbons. The composition may also include various other ingredients such as phosphatidylserine, water, glycerin, and several botanical extracts, among others.

Further claims detail the specific concentrations of the components and the potential inclusion of additional peptides and lipids. For instance, the composition may contain palmitoyl or myristoyl variants of the tripeptide-1 and hexapeptide-12. The patent outlines that phosphatidylserine can be included at a concentration of 0.025 wt. % to 0.1 wt. %, and it provides a comprehensive list of optional ingredients, including various oils, extracts, and stabilizers. The claims also specify the average particle size of the liposomes, with preferred ranges between 150 to 220 nanometers, and detail the specific weight percentages for each ingredient, ensuring a precise formulation for the topical application.

To know more about GlobalData’s detailed insights on Galderma, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies